Research progress on the regulatory role and mechanisms of the Hippo signaling pathway in the pathogenesis of congenital heart disease

Qing-Xiu LI, Jia-Yi CHEN, Yi-Bing ZHU, Hai-Bo LI

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (8) : 1025-1030.

PDF(556 KB)
HTML
PDF(556 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (8) : 1025-1030. DOI: 10.7499/j.issn.1008-8830.2510086
REVIEW

Research progress on the regulatory role and mechanisms of the Hippo signaling pathway in the pathogenesis of congenital heart disease

Author information +
History +

Abstract

Congenital heart disease (CHD) is the most common birth defect, with a complex pathogenesis involving genetic, environmental, and signaling pathway abnormalities. The Hippo signaling pathway is an evolutionarily conserved key regulator of organ size and tissue homeostasis. Its core components mammalian sterile 20-like kinase 1/2 and large tumor suppressor kinase 1/2 phosphorylate the downstream effectors YAP/TAZ, regulating cell proliferation, differentiation, and apoptosis. Dysfunction of the Hippo pathway is closely related to the occurrence and development of multiple CHD types. This review summarizes the core components and regulatory mechanisms of the Hippo pathway, describes its role in cardiac development, and elucidates the molecular mechanisms by which it contributes to ventricular septal defect, tetralogy of Fallot, and left ventricular noncompaction cardiomyopathy, aiming to provide a new theoretical basis for the early diagnosis and treatment of CHD.

Key words

Congenital heart disease / Hippo signaling pathway / Cardiac development / Ventricular septal defect

Cite this article

Download Citations
Qing-Xiu LI , Jia-Yi CHEN , Yi-Bing ZHU , et al. Research progress on the regulatory role and mechanisms of the Hippo signaling pathway in the pathogenesis of congenital heart disease[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(8): 1025-1030 https://doi.org/10.7499/j.issn.1008-8830.2510086

References

[1]
Xu J, Li Q, Deng L, et al. Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021[J]. Front Cardiovasc Med, 2025, 12: 1522644. PMCID: PMC12122482. DOI: 10.3389/fcvm.2025.1522644 .
[2]
刘玉梅, 刘天钰, 农绍汉, 等. 先天性心脏病相关性神经发育障碍的研究进展[J]. 中国当代儿科杂志, 2024, 26(11): 1231-1237. PMCID: PMC11601115. DOI: 10.7499/j.issn.1008-8830.2406063 .
[3]
Deng L, Li Q, Cheng Z. Evaluating the global, regional, and national burden of congenital heart disease in infants younger than 1 year: a 1990-2021 systematic analysis for the GBD study 2021[J]. Front Pediatr, 2025, 13: 1467914. PMCID: PMC11966173. DOI: 10.3389/fped.2025.1467914 .
[4]
赵趣鸣, 黄国英. 先天性心脏病的早期发现、诊断和治疗原则[J]. 中华儿科杂志, 2024, 62(2): 190-192. DOI: 10.3760/cma.j.cn112140-20231031-00337 .
[5]
Dotson A, Covas T, Halstater B, et al. Congenital heart disease[J]. Prim Care, 2024, 51(1): 125-142. DOI: 10.1016/j.pop.2023.07.007 .
[6]
Guo P, Wan S, Guan KL. The hippo pathway: organ size control and beyond[J]. Pharmacol Rev, 2025, 77(2): 100031. DOI: 10.1016/j.pharmr.2024.100031 .
[7]
顾燕妮, 谢春毅. Hippo信号通路与心脏病[J]. 国际心血管病杂志, 2021, 48(5): 281-284. DOI: 10.3969/j.issn.1673-6583.2021.05.007 .
[8]
Zhao X, Tang L, Le TP, et al. Yap and Taz promote osteogenesis and prevent chondrogenesis in neural crest cells in vitro and in vivo [J]. Sci Signal, 2022, 15(757): eabn9009. PMCID: PMC9938793. DOI: 10.1126/scisignal.abn9009 .
[9]
Kibalnyk Y, Afanasiev E, Noble RMN, et al. The chromatin regulator Ankrd11 controls cardiac neural crest cell-mediated outflow tract remodeling and heart function[J]. Nat Commun, 2024, 15(1): 4632. PMCID: PMC11217281. DOI: 10.1038/s41467-024-48955-1 .
[10]
Hill MC, Kadow ZA, Long H, et al. Integrated multi-omic characterization of congenital heart disease[J]. Nature, 2022, 608(7921): 181-191. PMCID: PMC10405779. DOI: 10.1038/s41586-022-04989-3 .
[11]
Chen X, Li Y, Luo J, et al. Molecular mechanism of Hippo-YAP1/TAZ pathway in heart development, disease, and regeneration[J]. Front Physiol, 2020, 11: 389. PMCID: PMC7191303. DOI: 10.3389/fphys.2020.00389 .
[12]
Zhong Z, Jiao Z, Yu FX. The Hippo signaling pathway in development and regeneration[J]. Cell Rep, 2024, 43(3): 113926. DOI: 10.1016/j.celrep.2024.113926 .
[13]
肖红, 宋亚锋, 黄燕君. 增殖分化视角下成年哺乳动物心肌再生研究进展[J]. 生命科学, 2023, 35(2): 203-211. DOI: 10.13376/j.cbls/2023027 .
[14]
Flinn MA, Link BA, O'Meara CC. Upstream regulation of the Hippo-Yap pathway in cardiomyocyte regeneration[J]. Semin Cell Dev Biol, 2020, 100: 11-19. PMCID: PMC7263368. DOI: 10.1016/j.semcdb.2019.09.004 .
[15]
Heallen T, Zhang M, Wang J, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size[J]. Science, 2011, 332(6028): 458-461. PMCID: PMC3133743. DOI: 10.1126/science.1199010 .
[16]
Lai JKH, Collins MM, Uribe V, et al. The Hippo pathway effector Wwtr1 regulates cardiac wall maturation in zebrafish[J]. Development, 2018, 145(10): dev159210. DOI: 10.1242/dev.159210 .
[17]
Li Y, Du J, Deng S, et al. The molecular mechanisms of cardiac development and related diseases[J]. Signal Transduct Target Ther, 2024, 9(1): 368. PMCID: PMC11666744. DOI: 10.1038/s41392-024-02069-8 .
[18]
Artap S, Manderfield LJ, Smith CL, et al. Endocardial hippo signaling regulates myocardial growth and cardiogenesis[J]. Dev Biol, 2018, 440(1): 22-30. PMCID: PMC5989000. DOI: 10.1016/j.ydbio.2018.04.026 .
[19]
Xiao Y, Hill MC, Zhang M, et al. Hippo signaling plays an essential role in cell state transitions during cardiac fibroblast development[J]. Dev Cell, 2018, 45(2): 153-169.e6. PMCID: PMC5947860. DOI: 10.1016/j.devcel.2018.03.019 .
[20]
Chen X, Yuan W, Li Y, et al. Role of Hippo-YAP1/TAZ pathway and its crosstalk in cardiac biology[J]. Int J Biol Sci, 2020, 16(13): 2454-2463. PMCID: PMC7378646. DOI: 10.7150/ijbs.47142 .
[21]
Ye L, Yin M, Xia Y, et al. Decreased Yes-associated protein-1 (YAP1) expression in pediatric hearts with ventricular septal defects[J]. PLoS One, 2015, 10(10): e0139712. PMCID: PMC4591351. DOI: 10.1371/journal.pone.0139712 .
[22]
Sharma V, Goessling LS, Brar AK, et al. Coxsackievirus B3 infection early in pregnancy induces congenital heart defects through suppression of fetal cardiomyocyte proliferation[J]. J Am Heart Assoc, 2021, 10(2): e017995. PMCID: PMC7955305. DOI: 10.1161/jaha.120.017995 .
[23]
Erhardt S. Yap and Taz are required for neural crest-derived cardiovascular development[D]. Houston: The University of Texas, 2022.
[24]
Di Toro A, Giuliani L, Smirnova A, et al. Myths to debunk: the non-compacted myocardium[J]. Eur Heart J , 22(Suppl L): L6-L10. PMCID: PMC7904063. DOI: 10.1093/eurheartj/suaa124 .
Suppl, 2020
[25]
Zou J, Ma W, Li J, et al. Neddylation mediates ventricular chamber maturation through repression of Hippo signaling[J]. Proc Natl Acad Sci U S A, 2018, 115(17): E4101-E4110. PMCID: PMC5924905. DOI: 10.1073/pnas.1719309115 .
[26]
Srivastava S. Domain-specific roles of Gpr126 in ventricular chamber development[D]. Erlangen: Friedrich-Alexander-Universität Erlangen-Nürnberg, 2021.
[27]
Mia MM, Singh MK. The Hippo signaling pathway in cardiac development and diseases[J]. Front Cell Dev Biol, 2019, 7: 211. PMCID: PMC6779857. DOI: 10.3389/fcell.2019.00211 .
[28]
Liu S, Tang L, Zhao X, et al. Yap promotes noncanonical Wnt signals from cardiomyocytes for heart regeneration[J]. Circ Res, 2021, 129(8): 782-797. PMCID: PMC8513110. DOI: 10.1161/circresaha.121.318966 .
[29]
Liu S, Li K, Wagner Florencio L, et al. Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction[J]. Sci Transl Med, 2021, 13(600): eabd6892. PMCID: PMC9476348. DOI: 10.1126/scitranslmed.abd6892 .
[30]
Singh A, Ramesh S, Cibi DM, et al. Hippo signaling mediators Yap and Taz are required in the epicardium for coronary vasculature development[J]. Cell Rep, 2016, 15(7): 1384-1393. PMCID: PMC4871746. DOI: 10.1016/j.celrep.2016.04.027 .
[31]
Peralta M, Ortiz Lopez L, Jerabkova K, et al. Intraflagellar transport complex B proteins regulate the Hippo effector Yap1 during cardiogenesis[J]. Cell Rep, 2020, 32(3): 107932. DOI: 10.1016/j.celrep.2020.107932 .
[32]
Kohela A, van Rooij E. Fibro-fatty remodelling in arrhythmogenic cardiomyopathy[J]. Basic Res Cardiol, 2022, 117(1): 22. PMCID: PMC9018639. DOI: 10.1007/s00395-022-00929-4 .
[33]
Simard C, Aize M, Chaigne S, et al. Ion channels in the development and remodeling of the aortic valve[J]. Int J Mol Sci, 2023, 24(6): 5860. PMCID: PMC10055105. DOI: 10.3390/ijms24065860 .
[34]
Duchemin AL, Vignes H, Vermot J. Mechanically activated piezo channels modulate outflow tract valve development through the Yap1 and Klf2-Notch signaling axis[J]. Elife, 2019, 8: e44706. PMCID: PMC6779468. DOI: 10.7554/eLife.44706 .

Footnotes

所有作者声明无利益冲突。

PDF(556 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/